1. Introduction: Polysaccharides and the Promise of Immunomodulation
Extracts from mushrooms and plants have been used in traditional medicine for centuries, and some have entered mainstream oncology in specific countries as adjuncts to conventional therapy. The most studied class of active compounds is the polysaccharides, particularly β-glucans, which can modulate immune function. A few mushroom-derived products — notably polysaccharide K (PSK) and lentinan — are approved as adjuncts in Japan, and plant compounds such as curcumin and green-tea catechins are widely promoted. This article reviews the biological rationale, the evidence, and the gap between marketing claims and demonstrated benefit.
2. Biological Rationale
Many mushroom polysaccharides are recognized by pattern-recognition receptors on innate immune cells — notably dectin-1 and complement receptor 3, which bind β-glucans. Activation of these pathways can enhance phagocytosis, cytokine production, and antigen presentation, providing a plausible mechanism for immune stimulation. This is genuine immunobiology, and it is why some β-glucans are studied as vaccine adjuvants. However, stimulating the immune system is not the same as controlling an established tumor, and the immunosuppressive microenvironment of cancer limits the effect of non-specific immune stimulation.
3. Specific Agents and Their Evidence
| Agent | Source | Status of evidence |
|---|---|---|
| Polysaccharide K (PSK) / PSP | Coriolus versicolor (turkey tail) | Approved in Japan as an adjunct after surgery/chemotherapy for gastric and colorectal cancer; Western trials inconclusive |
| Lentinan | Shiitake (Lentinula edodes) | Approved in Japan with chemotherapy for gastric cancer; evidence limited outside Japan |
| Grifola frondosa (maitake) D-fraction | Maitake | Preliminary, low-quality trials |
| Ganoderma lucidum (reishi) | Reishi | No established clinical benefit |
| Agaricus blazei | Himematsutake | No established clinical benefit |
| Curcumin | Turmeric | Preclinical robust; clinical trials limited by poor bioavailability; no established antitumor role |
| Green tea catechins (EGCG) | Green tea | Observational associations; no established treatment role |
| Resveratrol | Grapes, berries | Preclinical; no established clinical benefit |
3.1. PSK and Lentinan
PSK and lentinan are the most clinically studied mushroom polysaccharides. In Japan they are used as adjuncts to chemotherapy, and randomized trials have reported improved survival in gastric and colorectal cancer in that setting. However, many of these trials were conducted decades ago, with methodological limitations, and they have not been replicated to the standard required for broader approval. Western oncology has not adopted these agents. Independent systematic reviews describe a possible survival benefit when combined with chemotherapy but rate the quality of evidence as low and the risk of bias as high.
3.2. Plant Extracts
Plant-derived compounds such as curcumin, resveratrol, and green-tea catechins show a variety of anticancer effects in laboratory studies and are the subject of many clinical trials. Their translation to clinical benefit has been hampered by poor bioavailability, and none has an established role as a cancer treatment. Observational studies linking green tea or curcumin consumption to lower cancer risk are subject to confounding and do not establish causation.
4. Why the Evidence Is Weak
Several recurring problems limit this field: small sample sizes, lack of blinding, use of surrogate endpoints, publication bias toward positive results, heterogeneity of products (extraction methods and active-compound content vary widely), and, for observational data, confounding. In addition, non-specific immune stimulation is a weak lever against established cancer relative to checkpoint inhibition or cellular therapy. These factors explain why decades of research have not produced a widely accepted mushroom- or plant-based cancer drug, with the partial exception of Japan’s adjunct approvals.
5. Safety and Interactions
Most mushroom extracts are well tolerated, but concerns exist. Herbal products can interact with chemotherapy and anticoagulants (for example, through effects on cytochrome P450 or platelet function), and high-dose green-tea extract has been associated with liver injury. Because dietary supplements are loosely regulated, contamination, adulteration, and mislabeling are real risks. Patients should disclose all supplement use to their oncology team.
6. Unresolved Questions and Speculative Directions
- Whether PSK, lentinan, or any related polysaccharide provides a reproducible survival benefit in well-designed modern trials is unresolved. [Marked for verification.]
- Whether β-glucans can be used to improve the efficacy of modern immunotherapies is an early but biologically reasonable research question.
7. Conclusion
Mushroom and plant extracts have a plausible immunological rationale, and a small number of mushroom polysaccharides are used as adjuncts in Japan with low-quality supporting evidence. Most mushroom and plant products marketed for cancer, however, lack proof of efficacy, and marketing claims greatly exceed the evidence. These agents should not replace conventional treatment; they may interact with cancer drugs and are variably regulated. The most defensible approach is to treat them as unproven adjuncts, disclosed to the treating team and ideally used only within research.
Sources and Key Research Centers
- National Cancer Institute — PDQ summaries on complementary and alternative medicine.
- Memorial Sloan Kettering Cancer Center — About Herbs — evidence-based monographs on mushroom and plant extracts.
- Cochrane Library — reviews of mushroom polysaccharides and herbal adjuncts in cancer.
- PSK adjunct trials in gastric/colorectal cancer — Japanese randomized trials and meta-analyses. [Citation details to be verified.]
- β-glucan immunobiology — literature on dectin-1 and complement receptor 3. [Citation details to be verified.]
- Green tea extract hepatotoxicity — case reports and safety reviews. [Citation details to be verified.]
- ClinicalTrials.gov — ongoing trials of curcumin, β-glucans, and mushroom extracts (search terms: curcumin cancer, lentinan, beta-glucan cancer).
Note: citation identifiers are provided where available; readers should confirm bibliographic details against the publisher’s record. This article is an editorial scientific overview and is not a medical recommendation.